Condition
Behçet's Syndrome (BS)
Total Trials
4
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Recruiting2
Active Not Recruiting1
Enrolling By Invitation1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06723106Phase 1Enrolling By Invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
NCT06371417Phase 1Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT07244614RecruitingPrimary
Ustekinumab in BEhçet's Syndrome STudy
NCT07073261Active Not RecruitingPrimary
Prospective Multiethnic Validation of the Behçet's Syndrome Overall Damage Index (BODI)
Showing all 4 trials